Found 317 clinical trials
A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents
clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The
- 0 views
- 04 Mar, 2021
- 1 location
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)
available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer
- 62 views
- 17 Mar, 2022
- 9 locations
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (SPARKLE)
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted
- 0 views
- 15 May, 2022
- 1 location
NICSO National Study: Physician - Nurse Monitoring Project About Oncological Adverse Events
The lacking adherence to guidelines on prevention and treatment of different chemotherapy, targeted therapy, and immunotherapy induced toxicities is the reason why there are a potential
- 0 views
- 22 Oct, 2021
- 1 location
Neoadjuvant Treatment Modalities in Esophageal Cancer
Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction …
- 0 views
- 06 Apr, 2021
- 1 location
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted
- 7 views
- 24 Feb, 2022
- 1 location
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on
- 1 views
- 22 Mar, 2022
- 541 locations
CPCT-02 Biopsy Protocol
of such "targeted" agents is an exciting new opportunity that promises to deliver more anti-cancer efficacy and less toxicity. Although targeted therapy has been a breakthrough in medical oncology
- 8 views
- 25 Jan, 2021
- 2 locations
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
tumor's HER2 is positive, the patient can receive targeted therapy (Herceptin) combined with tamoxifen or placebo. The follow-up time will be eight years. The aim of this trial is to evaluate the
- 30 views
- 18 May, 2022
- 17 locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
proportion of all relapses. Targeted therapy is also used in the form of the proteasome inhibitor bortezomib for patients with pB-ALL and slow response to the drugs of the induction chemotherapy with the
- 870 views
- 13 Feb, 2022
- 93 locations